Where is Deerfield's headquarters located?

Deerfield's headquarters is located in New York City (United States).

How big is Deerfield's investment team?

Deerfield has a team of 16, including 9 partners.

How many companies has Deerfield invested in?

Deerfield has invested in 228 companies, including BridgeBio & Invitae.

Which companies has Deerfield invested in lately?

Ray Therapeutics & Neomorph are the latest investments by Deerfield.

What sectors does Deerfield focus on for investments?

Top sectors in Deerfield's portfolio are Life Sciences (177 investments) and High Tech (41 investments).

How many exits has Deerfield been involved in?

Deerfield's portfolio has seen 67 IPOs and 74 acquisitions.

How many unicorns are there in Deerfield's portfolio?

There are 3 unicorns in Deerfield's portfolio.

Deerfield - 2026 Investor Profile, Portfolio, Team & Investment Trends

1. BridgeBio

Developer of therapeutics for the treatment of genetic diseases. It utilizes a mapping of various genetic disease landscapes to identify opportunities for therapeutic intervention. The company's drug candidates include PTCH1-inhibitor for Gorlin syndrome and S1P-lyase inhibitor for Darier disease and Hailey-Hailey disease and others.

Key facts about BridgeBio

Founded Year: 2015
Location: Palo Alto (United States)
Annual Revenue: $500M - $1B as on Dec 31, 2025
Stage: Public
Total Funding till date: $434M
Employee Count: 948 as on Apr 30, 2026
Investors: Athyrium Capital Management, Aisling Capital and 20 Others
Latest Funding Round: Post IPO, Apr 30, 2024, $*****
Highlight: Public

2. Invitae

Provider of home-based genetic tests for individuals. The platform enables users to request a test online with the help of doctors to collect saliva samples to detect genetic diseases. Users can get results online and share them with doctors.

Key facts about Invitae

Founded Year: 2010
Location: San Francisco (United States)
Annual Revenue: $500M - $1B as on Dec 31, 2022
Stage: Public
Total Funding till date: $190M
Employee Count: 677 as on Jun 30, 2026
Investors: Scheuermann Investment, Oberland Capital and 22 Others
Latest Funding Round: Post IPO, Apr 05, 2021, $*****
Highlight: Public

3. Schrodinger

Provider of a web-based simulation and modelling tool for computational chemistry and drug discovery. It has developed a software solution for computational chemistry and material designing. Its proprietary platform is a simulation-based modelling platform that offers protein-protein docking, protein modelling, protein engineering, and antibody modelling study. It also offers products that help in treating oesophageal, ovarian, pancreatic, breast, and lung cancers.

Key facts about Schrodinger

Founded Year: 1990
Location: New York City (United States)
Annual Revenue: $100M - $500M as on Dec 31, 2025
Last Known Valuation: $*****
Stage: Acquired
Total Funding till date: $162M
Employee Count: 1,002 as on Jun 30, 2026
Investors: HTIF, Laurion Capital and 16 Others
Latest Funding Round: Grant (prize money), Nov 18, 2021, $*****
Highlight: Acquired

4. Insulet

Manufacturer of wearable, tubeless insulin delivery systems for diabetes management. The company develops and provides simple, connected devices for continuous insulin delivery. These devices offer an alternative to multiple daily injections. The company focuses on research and development to improve its technologies.

Key facts about Insulet

Founded Year: 2000
Location: Boston (United States)
Annual Revenue: $1B+ as on Dec 31, 2025
Stage: Public
Total Funding till date: $120M
Employee Count: 5,306 as on Jun 30, 2026
Investors: Piper Jaffray, Orbimed and 13 Others
Latest Funding Round: Post IPO, Jun 03, 2014, $*****
Highlight: Public

5. Spark Therapeutics

Developer of gene therapy for rare diseases. It offers engineered adeno associated viruses to deliver the target gene sequence to the patient for RPE-65 mediated inherited retinal dystrophies. The company is also developing therapies for choroideremia, hemophilia A&B, and neurodegenerative diseases such as Batten's disease.

Key facts about Spark Therapeutics

Founded Year: 2013
Location: Philadelphia (United States)
Annual Revenue: $50M - $100M as on Dec 31, 2018
Last Known Valuation: $*****
Stage: Acquired
Total Funding till date: $82.8M
Employee Count: 304 as on Mar 31, 2026
Investors: Brookside Capital, T. Rowe Price and 6 Others
Latest Funding Round: Series B, May 23, 2014, $*****
Highlight: Acquired

View the full list of portfolio companies

Deerfield has invested in 233 companies over the last 20 years, with an average of 13 new investments annually in the last 10 years. In 2025, it made 10 investments, while as of Apr 2026, it has made 3 investments in this year. Its most recent first time investment was in Excelsior Sciences and most recent follow-on round was in Ray Therapeutics.

Here are Deerfield's Year-on-Year Investment Trends:

Year	No. of Investments
Year	1^st Round	Follow-on	Total
2026 (YTD)	0	3	3
2025	7	3	10
2024	11	5	16
2023	9	3	12
2022	12	4	16
2021	24	9	33
2020	18	4	22
2019	13	5	18
2018	22	4	26
2017	8	5	13

View all investments by Deerfield

Deerfield has made 44 investments in Series A stage with an average round size of $42.5M, 40 investments in Series C stage with an average round size of $72.1M and 39 investments in Series B stage with an average round size of $60.5M.

Here are Deerfield's investments by stage:

Stage of entry	No. of Investments
Series A	44
Series C	40
Series B	39
Post IPO	25
Series D	20
Others	28

Note: We have considered here, only first round of investments

View all investments by Deerfield

Deerfield has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Healthcare. Notably, it has invested in 192 Tech companies, 182 Enterprise (B2B) companies, 55 Software companies and at least 33 companies focusing on Tech hardware.

Here are Deerfield's investments by sector:

Sector	No. of Investments
Life Sciences	155
High Tech	39
Enterprise Applications	34
HealthTech	32
Healthcare	16
Others	51

Note: We have considered here, only first round of investments

View all investments by Deerfield

Deerfield has made most investments in United States (178), followed by Israel where it has made 5 investments.

Here are Deerfield's investments by geography:

Country	No. of Investments
United States	178
Israel	5
Canada	3
United Kingdom	3
France	2
Others	5

Note: We have considered here, only first round of investments

View all investments by Deerfield

Deerfield has made 3 investments in 2026 so far. Ray Therapeutics and Neomorph are the latest among them.

Here are the most recent investments by Deerfield:

Filter this list

Date	Company	Location	Round Details	Round Amount	Co-Investors
Apr 21, 2026	Ray Therapeutics	United States	Series B	2754	Janus Henderson Investors [+9]
Apr 13, 2026	Neomorph	United States	Series B	8503	Longwood Fund [+3]
Feb 26, 2026	SHINE Technologies	United States	Series D	5240	NantWorks [+4]
Dec 03, 2025	Excelsior Sciences	United States	Series A	7977	Khosla Ventures [+5]
Sep 25, 2025	Axon Therapies	United States	Series A	1432	Earlybird [+3]

See more recent investments made by Deerfield

Deerfield has 3 unicorns in its portfolio - Somatus, Headspace and LetsGetChecked. The most recent unicorn in their portfolio is Somatus. It became a unicorn in 2022, 1 years after Deerfield first invested in it.

Here is a list of unicorns in Deerfield's portfolio:

Filter this list

Tracxn Score	Company	Short Description	Founded year	Sector	Location	Company Stage	First Investment/ Acquisition Details
47	Somatus	Software enabled concierge services company to help manage chronic kidney disease	2015	HealthTech [+1]	Dunn Loring	Series E	doxsizd
72	Headspace	Provider of mental health support services via application and human care	2010	HealthTech [+2]	Santa Monica	Series C	swmpynf
56	LetsGetChecked	Online platform to order at home diagnostic tests for all health conditions	2013	HealthTech	Dublin	Series D	dzkfpfs

View more details about unicorns in Deerfield's portfolio

67 of Deerfield's portfolio companies have become public. Parabilis Medicines got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jun 2026 at marketcap of $2.33B and In Silico got listed on the Hong Kong Exchanges (HKG) at marketcap of $1.72B.

Here are Deerfield's portfolio companies that went public:

Filter this list

Company	IPO Date	First Invested on	First Round of Investment	Round Size
Parabilis Medicines	Jun 10, 2026	Nov 17, 2022	Series D	1636
In Silico	Dec 30, 2025	Jun 22, 2021	Series C	6095
Bicara Therapeutics	Sep 13, 2024	Dec 12, 2023	Series C	1423
Fractyl	Feb 02, 2024	Nov 30, 2017	Series D	8088
ARS Pharmaceuticals	Sep 15, 2022	Dec 19, 2018	Series C	1902

View more details about public companies in Deerfield's portfolio

74 companies from Deerfield's portfolio have been acquired. The most recent acquisition was Concert in Jul 2026 by Lyric for $*****.

Here are Deerfield's portfolio companies that got acquired most recently:

Filter this list

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
Concert	Jul 15, 2026	Jan 08, 2018	Series B	9877
Nuvalent	Jun 09, 2026	Jan 27, 2021	Series A	7587
Assertio	May 13, 2026	Mar 12, 2015	Conventional Debt	6952
CathWorks	Apr 20, 2026	Feb 04, 2019	Series C	1400
Terns Pharmaceutical	Mar 25, 2026	Jan 05, 2021	Series C	4011

View all acquired companies in Deerfield's portfolio

Deerfield has a team of 16 members including 9 Partners and 1 Principal located in United States.

Here is a list of top team members in Deerfield:

Name	Designation	Location	Contact Details
Alex Karnal	Partner	New York City	1 Email
David Clark	Partner	Charlotte	1 Email
Elliot Press	Partner	-	2 Emails
Jonathan Leff	Partner	New York City	-
Robert Jackson	Partner	Saint Louis	1 Email
Steve Hochberg	Partner	United States	1 Email
Timothy Leahy	Partner	New York City	1 Email
Dominic Viola	Partner	United States	1 Email
Amanda Sellers	Partner	United States	1 Email
Bob Josefsberg	Principal	New York	1 Email

View team details of Deerfield

Over the past 20 years, 1076 investors have co-invested in Deerfield's portfolio companies. This includes funds and angels.

Invested before Deerfield: HHS, Orbimed and 479 others have invested in rounds before Deerfield. There are 17 companies where HHS has invested before Deerfield and 10 companies where Orbimed has invested before Deerfield.
Top Co-investors of Deerfield: 341 investors entered a company along with Deerfield. These include investors like RA Capital Management (20 companies).
Invested after Deerfield: A total of 254 investors have invested in Deerfield's portfolio after their investments. Top Investors include RA Capital Management (8 companies) and Perceptive Advisors (7 companies).